{"id":"https://openalex.org/W4308381990","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","title":"1086 NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors","display_name":"1086 NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308381990","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1086"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1086","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1128.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1128.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040423604","display_name":"Damon J. Hamel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Damon Hamel","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021648840","display_name":"Marlene Hennessy","orcid":"https://orcid.org/0000-0003-0274-7653","observed_orcids":["https://orcid.org/0000-0003-0274-7653"]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marlene Hennessy","raw_affiliation_strings":["Exelixis, Alameda, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis, Alameda, CA, USA","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067117690","display_name":"Sarah A. Ingersoll","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Ingersoll","raw_affiliation_strings":["Amgen, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008439622","display_name":"Olga Zemska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Olga Zemska","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002768783","display_name":"Phi Quatch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phi Quatch","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110310289","display_name":"Rhoneil L. Pena","orcid":"https://orcid.org/0009-0008-0077-7107","observed_orcids":["https://orcid.org/0009-0008-0077-7107"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rhoneil Pena","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Thomas Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Chang","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Doherty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Doherty","raw_affiliation_strings":["Exelixis, Alameda, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis, Alameda, CA, USA","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Guifen Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152259","display_name":"Sutro Biopharma (United States)","ror":"https://ror.org/05xybd718","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152259"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guifen Xu","raw_affiliation_strings":["Sutro BioPharma, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sutro BioPharma, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210152259"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014264632","display_name":"Arkopal Choudhury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arkopal Choudhury","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101830789","display_name":"Danni Yu","orcid":"https://orcid.org/0000-0002-2468-6030","observed_orcids":["https://orcid.org/0000-0002-2468-6030"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danni Yu","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008359538","display_name":"Werner Rubas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152259","display_name":"Sutro Biopharma (United States)","ror":"https://ror.org/05xybd718","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152259"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Werner Rubas","raw_affiliation_strings":["Sutro BioPharma, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sutro BioPharma, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210152259"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089543099","display_name":"Christie P. Fanton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christie Fanton","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005739369","display_name":"Brian R. Vuillemenot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Vuillemenot","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008451092","display_name":"Saul Kivim\u00e4e","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saul Kivimae","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102507184","display_name":"Takahiro Miyazaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takahiro Miyazaki","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5011698346","display_name":"Jonathan Zalevsky","orcid":"https://orcid.org/0000-0003-2707-1709","observed_orcids":["https://orcid.org/0000-0003-2707-1709"]},"institutions":[{"id":"https://openalex.org/I2800689049","display_name":"Nektar Therapeutics (United States)","ror":"https://ror.org/03p1cbx82","country_code":"US","type":"company","lineage":["https://openalex.org/I2800689049"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Zalevsky","raw_affiliation_strings":["Nektar Therapeutics, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nektar Therapeutics, San Francisco, CA, USA","institution_ids":["https://openalex.org/I2800689049"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1128","last_page":"A1128"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5228999853134155,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.5228999853134155,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.3246999979019165,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.09769999980926514,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/polymer-conjugation","display_name":"polymer conjugation","score":0.6830000281333923},{"id":"https://openalex.org/keywords/ifngr1","display_name":"IFNGR1","score":0.8769999742507935},{"id":"https://openalex.org/keywords/heparin-binding","display_name":"heparin binding","score":0.8849999904632568},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8040000200271606},{"id":"https://openalex.org/keywords/stat1-activation","display_name":"STAT1 activation","score":0.6460000276565552},{"id":"https://openalex.org/keywords/mhc-class-i-upregulation","display_name":"MHC class I upregulation","score":0.8100000023841858},{"id":"https://openalex.org/keywords/pd-l1-upregulation","display_name":"PD-L1 upregulation","score":0.7860000133514404},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.8320000171661377},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9259999990463257},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9769999980926514},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6650000214576721},{"id":"https://openalex.org/keywords/b16f10-melanoma","display_name":"B16F10 melanoma","score":0.890999972820282},{"id":"https://openalex.org/keywords/tumor-antigen-presentation","display_name":"tumor antigen presentation","score":0.3019999861717224}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5009689331054688},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.48105692863464355},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4808921813964844},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.447888046503067},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.43499937653541565},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43433430790901184},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39758479595184326},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.35004591941833496},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28470611572265625},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2407413125038147},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1541716456413269},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.1086","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1128.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1086","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1086","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1128.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308381990.pdf","grobid_xml":"https://content.openalex.org/works/W4308381990.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2727010309","https://openalex.org/W4318542660","https://openalex.org/W2269860277","https://openalex.org/W2600862992","https://openalex.org/W2053414473","https://openalex.org/W3161701572","https://openalex.org/W2044928211","https://openalex.org/W4317733675","https://openalex.org/W2548531298","https://openalex.org/W7169158810"],"abstract_inverted_index":{"Background":[0],"Interferon":[1],"gamma":[2,88],"(IFNg)":[3],"cytokine":[4,381],"induces":[5],"cellular":[6],"antigen":[7,20,335],"presentation":[8],"and":[9,31,56,59,77,92,114,120,130,137,172,176,223,230,249,289,306,330,346,360,395,415,421,433,439],"has":[10,164,239],"great":[11],"potential":[12,199,375,388],"in":[13,110,118,121,126,144,213,265,365,383],"cancer":[14,384],"treatment":[15],"through":[16],"enhancement":[17,138],"of":[18,34,75,84,103,139,251,333,376,418],"tumor":[19,111,149,214,266,277,307,334,339,369],"specific":[21],"cytotoxic":[22,340],"T":[23,315,341,356],"cell":[24,112,342],"response.":[25],"However,":[26],"the":[27,32,73,145,197,258,374,387,397,411,422,431,443],"unfavorable":[28],"pharmacokinetics":[29],"(PK)":[30],"pleiotropy":[33],"native":[35,259],"IFNg":[36,46,154],"have":[37],"limited":[38],"its":[39,79],"therapeutic":[40],"potential.":[41],"NKTR-288":[42,76,85,104,163,195,209,238,261,318,377],"is":[43,231,319],"a":[44,152,158,240,275,279,320,351,366,379],"polymer-conjugated":[45],"mutein,":[47],"designed":[48],"to":[49,63,86,168,174,182,189,220,227,389],"improve":[50],"exposure":[51,212],"by":[52,96,107,410,442],"increasing":[53,338],"hydrodynamic":[54,166],"radius":[55,167],"reducing":[57,186],"receptor":[58,89],"heparin":[60,93,177],"binding":[61],"affinity":[62,180],"provide":[64],"optimized":[65,325],"on-target":[66],"pharmacodynamics":[67],"(PD).":[68],"Here,":[69],"we":[70],"report":[71],"on":[72,204,425],"discovery":[74],"investigate":[78],"pharmacological":[80,326],"properties.":[81],"Methods":[82],"Binding":[83],"interferon":[87],"1":[90],"(IFNGR1)":[91],"was":[94,105,124,142,310],"measured":[95,106,125,143],"surface":[97],"plasmon":[98],"resonance.":[99],"The":[100],"biological":[101],"activity":[102],"pSTAT1":[108,202],"induction":[109,203,248,332],"lines":[113],"primary":[115],"myeloid":[116],"cells":[117],"vitro":[119],"vivo.":[122],"PK/PD":[123,242],"nonhuman":[127],"primates":[128],"(NHP),":[129],"human":[131],"xenograft":[132],"mouse":[133,146,153,281,352],"models.":[134],"Anti-tumor":[135],"efficacy":[136,286,291,364,394],"checkpoint":[140,272,362,392],"blockade":[141,363,393],"syngeneic":[147,276],"B16F10":[148],"model":[150],"using":[151],"polymer":[155],"conjugate":[156,282,354],"as":[157,378],"surrogate":[159,280,353],"for":[160,201,328,436],"NKTR-288.":[161],"Results":[162],"increased":[165,290],"slow":[169],"renal":[170],"clearance":[171,187],"binds":[173],"IFNGR1":[175],"with":[178,257,271,294,324,386],"reduced":[179],"compared":[181],"recombinant":[183],"IFNg1b,":[184],"thereby":[185],"due":[188],"target-mediated":[190],"drug":[191],"deposition.":[192],"In":[193,207,274],"vitro,":[194],"maintains":[196],"maximum":[198],"(Emax)":[200],"target":[205],"cells.":[206,316],"vivo,":[208],"shows":[210],"durable":[211],"bearing":[215],"mice":[216],"(half-life":[217],"[T\u00bd]":[218],"18.2":[219],"24.2":[221],"hr)":[222,229],"NHP":[224],"(T\u00bd":[225],"31.6":[226],"37.3":[228],"well":[232,304],"tolerated":[233,305],"at":[234],"pharmacologically":[235],"active":[236],"doses.":[237],"desirable":[241],"profile":[243],"that":[244],"can":[245,254],"attain":[246],"greater":[247],"duration":[250],"MHCI":[252],"than":[253],"be":[255],"achieved":[256],"cytokine.":[260],"also":[262],"upregulates":[263],"PD-L1":[264],"tissue":[267],"supporting":[268],"combination":[269],"therapy":[270],"inhibitors.":[273],"model,":[278],"exhibited":[283],"significant":[284],"anti-tumor":[285,358],"(57%":[287],"TGI),":[288],"when":[292],"combined":[293],"anti-PD-1":[295],"(73%":[296],"TGI)":[297],"or":[298,447],"anti-PD-L1":[299],"(68%":[300],"TGI).":[301],"Treatments":[302],"were":[303,405],"growth":[308],"inhibition":[309],"immune":[311,344],"system":[312],"mediated,":[313],"requiring":[314],"Conclusions":[317],"novel":[321,380],"IFNGR":[322],"agonist":[323],"properties":[327],"tolerable":[329],"sustained":[331],"presentation,":[336],"potentially":[337],"response,":[343],"infiltration,":[345],"TME":[347],"modification.":[348],"As":[349],"evidence,":[350],"demonstrated":[355],"cell-mediated":[357],"activity,":[359],"enhanced":[361],"low-MHCI":[367],"\u201ccold\u201d":[368],"model.":[370],"These":[371],"results":[372],"highlight":[373],"immunotherapy":[382],"patients,":[385],"enhance":[390],"PD-1/PD-L1":[391],"broaden":[396],"responsive":[398],"patient":[399],"population.":[400],"Ethics":[401],"Approval":[402],"Animal":[403,413,426],"studies":[404,429],"performed":[406],"under":[407],"protocols":[408],"approved":[409],"Institutional":[412],"Care":[414],"Use":[416],"Committee":[417],"Nektar":[419],"Therapeutics":[420],"Canadian":[423,448],"Council":[424],"Care.":[427],"All":[428],"met":[430],"ethical":[432],"humane":[434],"criteria":[435],"transportation,":[437],"housing,":[438],"care":[440,450],"established":[441],"US":[444],"NIH":[445],"guidelines":[446],"animal":[449],"regulators.":[451]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2022-11-11T00:00:00"}